Tamzid Rahman, DO
Ophthalmology · Portland, MENPI 1538629696
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,895 of the $3,150 with a category attached, or 60.1%. 12 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 58.5% of the total. Reporting peaked in 2023 at $1,746 and has fallen 77.7% since, to $389 in 2025.
Across 39 payments — averaging $80.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- AbbVie$353
- Dompe US, Inc.$202
- Amgen$182
- Alcon$164
- Ocular Therapeutix, Inc.$147
- plus $259 from 6 others
What the payments were for
- Travel & lodging$1,15637%
- Food & beverage$1,89560%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 17 | $1,844 |
| AbbVie(2 entities) | 4 | $353 |
| Dompe US, Inc. | 3 | $202 |
| Amgen | 2 | $182 |
| Alcon | 3 | $164 |
| Ocular Therapeutix, Inc. | 1 | $147 |
| Tarsus Pharmaceuticals, Inc. | 2 | $73 |
| Mallinckrodt Hospital Products Inc. | 2 | $60 |
| Rxsight Inc | 2 | $52 |
| Glaukos Corporation | 1 | $30 |
| Carl Zeiss Meditec USA, Inc. | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$1,360
- STELLARIS ELITE$1,258
- Crystalens Accommodating IOL (AT-52AO)$1,258
- Trulign IOL$1,258
- Akreos AO IOL$1,258
- DURYSTA$234
- Oxervate$150
- DEXTENZA$147
- TEPEZZA$118
- Centurion$111
How this compares
$3,150 in reported general payments places this provider in the 85th percentile of 74 ophthalmology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 51 | $1,570 |
| MoxifloxacinMoxifloxacin Hcl | 35 | $641 |
| Ketorolac Tromethamine | 29 | $393 |
| Latanoprost | 15 | $115 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Portland
- Charles ZacksPortland$36K
- Hallie HahnPortland$5K
- Samuel SolishPortland$4K
- Ravindra ShahPortland$4K
- Richard FrancePortland$4K
- Margaret PollardPortland$1K
- Jackie NguyenPortland$1K
- Adam SisePortland$1K
- John LippincottPortland$994
- Benjamin FowlerPortland$763
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.